Development of MTL-CEBPA: Small activating RNA drug for hepatocellular carcinoma

Current Pharmaceutical Biotechnology

Volumn 19, Issue 8, 2018, Pages 611-621

  Setten, Ryan L ^a   Lightfoot, Helen L ^b   Habib, Nagy A ^c   Rossi, John J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MiNA Therapeutics Ltd   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cebp ; Hepatocellular carcinoma; Liver; Mina therapeutics; Mtl cebpa; Rna therapeutics; Sarna

Indexed keywords

ALPHA FETOPROTEIN; ARGONAUTE 2 PROTEIN; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; CCAAT ENHANCER BINDING PROTEIN ALPHA; COLLAPSIN RESPONSE MEDIATOR PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DIETHYLNITROSAMINE; DOUBLE STRANDED RNA; GAP JUNCTION PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; KRUPPEL LIKE FACTOR 4; MTL CEBPA; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; RNA; RNA HELICASE; SMALL ACTIVATING RNA; TRANSCRIPTION FACTOR MAFA; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN A; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN; SMALL INTERFERING RNA; SMALL UNTRANSLATED RNA; TRANSCRIPTION FACTOR;

CELL DIFFERENTIATION; DNA BINDING; GENE CONTROL; GENE EXPRESSION; GENE THERAPY; HAPLOINSUFFICIENCY; HIGH-FAT DIET-INDUCED STEATOHEPATITIS; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MRNA EXPRESSION LEVEL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVIEW; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; PHYSIOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CCAAT-ENHANCER-BINDING PROTEINS; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HUMANS; LIVER NEOPLASMS; RNA, DOUBLE-STRANDED; RNA, SMALL INTERFERING; RNA, SMALL UNTRANSLATED; TRANSCRIPTION FACTORS;

EID: 85055185517     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201019666180611093428     Document Type: Review

References (128)

1. Stein, C.A.; Castanotto, D. FDA-approved oligonucleotide therapies in 2017. Mol. Ther., 2017, 25(5), 1069-1075.
2. Geary, R.S.; Norris, D.; Yu, R.; Bennett, C.F. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev., 2015, 87, 46-51.
3. Juliano, R.L. The delivery of therapeutic oligonucleotides. Nucleic Acids Res., 2016, 44(14), 6518-6548.
4. Bennett, C.F.; Swayze, E.E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol., 2010, 50, 259-293.
5. Lightfoot, H.L.; Hall, J. Target mRNA inhibition by oligonucleotide drugs in man. Nucleic Acids Res., 2012, 40(21), 10585-10595.
6. Cyranoski, D. CRISPR gene-editing tested in a person for the first time. Nature, 2016, 539(7630), 479.
7. Reebye, V.; Saetrom, P.; Mintz, P.J.; Huang, K.W.; Swiderski, P.; Peng, L.; Liu, C.; Liu, X.; Lindkaer-Jensen, S.; Zacharoulis, D.; Kostomitsopoulos, N.; Kasahara, N.; Nicholls, J.P.; Jiao, L.R.; Pai, M.; Spalding, D.R.; Mizandari, M.; Chikovani, T.; Emara, M.M.; Haoudi, A.; Tomalia, D.A.; Rossi, J.J.; Habib, N.A. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology, 2014, 59(1), 216-227.
8. Itaka, K., Development of mRNA-based therapeutics. Nihon Yakurigaku Zasshi, 2016, 148(4), 190-196.
9. Sergeeva, O.V.; Koteliansky, V.E.; Zatsepin, T.S. mRNA-Based therapeutics-advances and perspectives. Biochemistry (Mosc), 2016, 81(7), 709-722.
10. Li, L.C.; Okino, S. T.; Zhao, H.; Pookot, D.; Place, R.F.; Urakami, S.; Enokida, H.; Dahiya, R. Small dsRNAs induce transcriptional activation in human cells. Proc. Natl. Acad. Sci. USA, 2006, 103(46), 17337-17342.
11. Janowski, B.A.; Younger, S.T.; Hardy, D.B.; Ram, R.; Huffman, K.E.; Corey, D.R. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat. Chem. Biol., 2007, 3(3), 166-173.
12. Place, R.F.; Li, L.C.; Pookot, D.; Noonan, E.J.; Dahiya, R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl. Acad. Sci. USA, 2008, 105(5), 1608-1613.
13. Voutila, J.; Reebye, V.; Roberts, T.C.; Protopapa, P.; Andrikakou, P.; Blakey, D.C.; Habib, R.; Huber, H.; Saetrom, P.; Rossi, J.J.; Habib, N.A. Development and mechanism of small activating RNA targeting CEBPA, a novel therapeutic in clinical trials for liver cancer. Mol. Ther., 2017, 25(12), 2705-2714.
14. Sarker, D.; Plummer, E.R.; Basu, B.; Meyer, T.; Huang, K.-W.; Evans, T.R.J.; Spalding, D.; Ma, Y.T.; Palmer, D.H.; Chee, C.E.; Toh, H.C.; Habib, N.A. First-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer. J. Clin. Oncol., 2017, 35(15_suppl), TPS2612-TPS2612.
15. Nakanishi, K. Anatomy of RISC: How do small RNAs and chaperones activate Argonaute proteins? Wiley interdisciplinary reviews. RNA, 2016, 7(5), 637-660.
16. Hannon, G.J, RNA interference. Nature, 2002, 418(6894), 244-251.
17. Robb, G.B.; Brown, K.M.; Khurana, J.; Rana, T.M. Specific and potent RNAi in the nucleus of human cells. Nat. Struct. Mol. Biol., 2005, 12(2), 133-137.
18. Lennox, K.A.; Behlke, M.A. Cellular localization of long noncoding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res., 2016, 44(2), 863-877.
19. Younger, S.T.; Corey, D.R. Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters. Nucleic Acids Res., 2011, 39(13), 5682-5691.
20. Gagnon, K.T.; Li, L.; Chu, Y.; Janowski, B.A.; Corey, D.R. RNAi factors are present and active in human cell nuclei. Cell Reports, 2014, 6(1), 211-221.
21. Gao, M.; Wei, W.; Li, M.M.; Wu, Y.S.; Ba, Z.; Jin, K.X.; Li, M.M.; Liao, Y.Q.; Adhikari, S.; Chong, Z.; Zhang, T.; Guo, C.X.; Tang, T.S.; Zhu, B.T.; Xu, X.Z.; Mailand, N.; Yang, Y.G.; Qi, Y.; Rendtlew Danielsen, J.M. Ago2 facilitates Rad51 recruitment and DNA double-strand break repair by homologous recombination. Cell Res., 2014, 24(5), 532-541.
22. Ameyar-Zazoua, M.; Rachez, C.; Souidi, M.; Robin, P.; Fritsch, L.; Young, R.; Morozova, N.; Fenouil, R.; Descostes, N.; Andrau, J. C.; Mathieu, J.; Hamiche, A.; Ait-Si-Ali, S.; Muchardt, C.; Batsche, E.; Harel-Bellan, A. Argonaute proteins couple chromatin silencing to alternative splicing. Nat. Struct. Mol. Biol., 2012, 19(10), 998-1004.
23. Weinmann, L.; Hock, J.; Ivacevic, T.; Ohrt, T.; Mutze, J.; Schwille, P.; Kremmer, E.; Benes, V.; Urlaub, H.; Meister, G. Importin 8 is a gene silencing factor that targets argonaute proteins to distinct mRNAs. Cell, 2009, 136(3), 496-507.
24. Wei, Y.; Li, L.; Wang, D.; Zhang, C.Y.; Zen, K. Importin 8 regulates the transport of mature microRNAs into the cell nucleus. J. Biologic. Chem., 2014, 289(15), 10270-10275.
25. Nishi, K.; Nishi, A.; Nagasawa, T.; Ui-Tei, K. Human TNRC6A is an Argonaute-navigator protein for microRNA-mediated gene silencing in the nucleus. RNA, 2013, 19(1), 17-35.
26. Schraivogel, D.; Schindler, S.G.; Danner, J.; Kremmer, E.; Pfaff, J.; Hannus, S.; Depping, R.; Meister, G. Importin-beta facilitates nuclear import of human GW proteins and balances cytoplasmic gene silencing protein levels. Nucleic Acids Res., 2015, 43(15), 7447-7461.
27. Core, L.J.; Waterfall, J.J.; Lis, J.T. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science, 2008, 322(5909), 1845-1848.
28. Seila, A.C.; Calabrese, J.M.; Levine, S.S.; Yeo, G.W.; Rahl, P.B.; Flynn, R.A.; Young, R.A.; Sharp, P.A. Divergent transcription from active promoters. Science, 2008, 322(5909), 1849-1851.
29. Schwartz, J.C.; Younger, S.T.; Nguyen, N.B.; Hardy, D.B.; Monia, B.P.; Corey, D.R.; Janowski, B.A. Antisense transcripts are targets for activating small RNAs. Nat. Struct. Mol. Biol., 2008, 15(8), 842-848.
30. Yue, X.; Schwartz, J.C.; Chu, Y.; Younger, S.T.; Gagnon, K.T.; Elbashir, S.; Janowski, B.A.; Corey, D.R. Transcriptional regulation by small RNAs at sequences downstream from 3' gene termini. Nat. Chem. Biol., 2010, 6(8), 621-629.
31. Liu, J.; Carmell, M.A.; Rivas, F.V.; Marsden, C.G.; Thomson, J.M.; Song, J.J.; Hammond, S.M.; Joshua-Tor, L.; Hannon, G.J. Argonaute2 is the catalytic engine of mammalian RNAi. Science, 2004, 305(5689), 1437-1441.
32. Haaland, R.E.; Herrmann, C.H.; Rice, A.P. siRNA depletion of 7SK snRNA induces apoptosis but does not affect expression of the HIV-1 LTR or P-TEFb-dependent cellular genes. J. Cellul. Physiol., 2005, 205(3), 463-470.
33. Matsui, M.; Chu, Y.; Zhang, H.; Gagnon, K.T.; Shaikh, S.; Kuchimanchi, S.; Manoharan, M.; Corey, D.R.; Janowski, B.A. Promoter RNA links transcriptional regulation of inflammatory pathway genes. Nucleic Acids Res., 2013, 41(22), 10086-10109.
34. Portnoy, V.; Lin, S.H.; Li, K.H.; Burlingame, A.; Hu, Z.H.; Li, H.; Li, L.C. saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription. Cell Res., 2016, 26(3), 320-335.
35. Chu, Y.; Yue, X.; Younger, S.T.; Janowski, B.A.; Corey, D.R. Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. Nucleic Acids Res., 2010, 38(21), 7736-7748.
36. Hu, J.; Chen, Z.; Xia, D.; Wu, J.; Xu, H.; Ye, Z.Q. Promoter-associated small double-stranded RNA interacts with heterogeneous nuclear ribonucleoprotein A2/B1 to induce transcriptional activation. Biochemic. J., 2012, 447(3), 407-416.
37. Lawrence, M.; Daujat, S.; Schneider, R. Lateral thinking: How histone modifications regulate gene expression. Trends Genet.: TIG, 2016, 32(1), 42-56.
38. Wang, X.; Wang, J.; Huang, V.; Place, R.F.; Li, L.C. Induction of NANOG expression by targeting promoter sequence with small activating RNA antagonizes retinoic acid-induced differentiation. Biochemic. J., 2012, 443(3), 821-828.
39. Voutila, J.; Saetrom, P.; Mintz, P.; Sun, G.; Alluin, J.; Rossi, J.J.; Habib, N.A.; Kasahara, N. Gene expression profile changes after short-activating RNA-mediated induction of endogenous pluripotency factors in human mesenchymal stem cells. Molecular therapy. Nucleic Acids, 2012, 1, e35.
40. Reebye, V.; Saetrom, P.; Mintz, P.J.; Rossi, J.J.; Kasahara, N.; Nteliopoulos, G.; Nicholls, J.; Haoudi, A.; Gordon, M.; Habib, N. A. A Short-activating RNA oligonucleotide targeting the islet beta-cell transcriptional factor MafA in CD34(+) Cells. Mol. Ther. Nucleic Acids, 2013, 2, e97.
41. Wang, T.; Li, M.; Yuan, H.; Zhan, Y.; Xu, H.; Wang, S.; Yang, W.; Liu, J.; Ye, Z.; Li, L.C., saRNA guided iNOS up-regulation improves erectile function of diabetic rats. J. Urol., 2013, 190(2), 790-798.
42. Ren, S.; Kang, M.R.; Wang, J.; Huang, V.; Place, R.F.; Sun, Y.; Li, L.C. Targeted induction of endogenous NKX3-1 by small activating RNA inhibits prostate tumor growth. Prostate, 2013, 73(14), 1591-1601.
43. Wang, J.; Huang, V.; Ye, L.; Barcena, A.; Lin, G.; Lue, T.F.; Li, L.C. Identification of small activating RNAs that enhance endogenous OCT4 expression in human mesenchymal stem cells. Stem Cells Developm., 2015, 24(3), 345-353.
44. Esseltine, J.L.; Shao, Q.; Huang, T.; Kelly, J.J.; Sampson, J.; Laird, D.W. Manipulating Cx43 expression triggers gene reprogramming events in dermal fibroblasts from oculodentodigital dysplasia patients. Biochemic. J., 2015, 472(1), 55-69.
45. Li, C.; Jiang, W.; Hu, Q.; Li, L.C.; Dong, L.; Chen, R.; Zhang, Y.; Tang, Y.; Thrasher, J.B.; Liu, C.B.; Li, B. Enhancing DPYSL3 gene expression via a promoter-targeted small activating RNA approach suppresses cancer cell motility and metastasis. Oncotarget, 2016, 7(16), 22893-22910.
46. Kalantari, R.; Hicks, J.A.; Li, L.; Gagnon, K.T.; Sridhara, V.; Lemoff, A.; Mirzaei, H.; Corey, D.R. Stable association of RNAi machinery is conserved between the cytoplasm and nucleus of human cells. RNA, 2016, 22(7), 1085-1098.
47. Hicks, J.A.; Li, L.; Matsui, M.; Chu, Y.; Volkov, O.; Johnson, K.C.; Corey, D.R. Human GW182 paralogs are the central organizers for RNA-mediated control of transcription. Cell Reports, 2017, 20(7), 1543-1552.
48. Nakajima, T.; Uchida, C.; Anderson, S.F.; Lee, C.G.; Hurwitz, J.; Parvin, J.D.; Montminy, M. RNA helicase A mediates association of CBP with RNA polymerase II. Cell, 1997, 90(6), 1107-1112.
49. Jaehning, J.A. The Paf1 complex: Platform or player in RNA polymerase II transcription? Biochim. et Biophysic. Acta, 2010, 1799(5-6), 379-388.
50. Krogan, N.J.; Dover, J.; Wood, A.; Schneider, J.; Heidt, J.; Boateng, M.A.; Dean, K.; Ryan, O.W.; Golshani, A.; Johnston, M.; Greenblatt, J.F.; Shilatifard, A. The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: Linking transcriptional elongation to histone methylation. Molecular cell, 2003, 11(3), 721-729.
51. Turunen, M.P.; Lehtola, T.; Heinonen, S.E.; Assefa, G.S.; Korpisalo, P.; Girnary, R.; Glass, C.K.; Vaisanen, S.; Yla-Herttuala, S. Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy. Circulat. Res., 2009, 105(6), 604-609.
52. Place, R.F.; Wang, J.; Noonan, E.J.; Meyers, R.; Manoharan, M.; Charisse, K.; Duncan, R.; Huang, V.; Wang, X.; Li, L.C., Formulation of small activating RNA into lipidoid nanoparticles inhibits xenograft prostate tumor growth by inducing p21 expression. Mol. Ther. Nucleic Acids, 2012, 1, e15.
53. Reebye, V.H.K.; Lin, V.; Jarvis, S.; Cutilas, P.; Dorman, S.; Ciriello, S.; Andrikakou, P.; Voutila, J.; Saetrom, P.; Mintz, P.J.; Reccia, I.; Rossi, J.J.; Huber, H.; Habib, R.; Kostomitsopoulos, N.; Blakey, D.; Habib N. Gene activation of CEBPA using saRNA: Preclinical studies of the first in human saRNA drug candidate for liver cancer. Oncogene, 2018, In press.
54. Li, L.-C., In: Advances in Experimental Medicine and Biology, RNA activation. 2017.
55. Tatiparti, K.; Sau, S.; Kashaw, S.K.; Iyer, A.K. siRNA Delivery Strategies: A comprehensive review of recent developments. Nanomaterials, 2017, 7(4), pii: E77.
56. Lekstrom-Himes, J.; Xanthopoulos, K.G. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J. Biologic. Chem., 1998, 273(44), 28545-28548.
57. Ramji, D.P.; Foka, P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem. J., 2002, 365(Pt 3), 561-75.
58. Tsukada, J.; Yoshida, Y.; Kominato, Y.; Auron, P.E. The CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-regulated system for gene regulation. Cytokine, 2011, 54(1), 6-19.
59. Nerlov, C. The C/EBP family of transcription factors: A paradigm for interaction between gene expression and proliferation control. Trends Cell Biol., 2007, 17(7), 318-324.
60. Friedman, A.D.; McKnight, S.L. Identification of two polypeptide segments of CCAAT/enhancer-binding protein required for transcriptional activation of the serum albumin gene. Genes Developm., 1990, 4(8), 1416-1426.
61. Nerlov, C.; Ziff, E.B. Three levels of functional interaction determine the activity of CCAAT/enhancer binding protein-alpha on the serum albumin promoter. Genes Developm., 1994, 8(3), 350-362.
62. Nerlov, C.; Ziff, E.B. CCAAT/enhancer binding protein-alpha amino acid motifs with dual TBP and TFIIB binding ability cooperate to activate transcription in both yeast and mammalian cells. EMBO J., 1995, 14(17), 4318-4328.
63. Osada, S.; Yamamoto, H.; Nishihara, T.; Imagawa, M., DNA binding specificity of the CCAAT/enhancer-binding protein transcription factor family. J. Biologic. Chem., 1996, 271(7), 3891-3896.
64. Landschulz, W.H.; Johnson, P.F.; McKnight, S.L. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science, 1988, 240(4860), 1759-1764.
65. Agre, P.; Johnson, P.F.; McKnight, S.L. Cognate DNA binding specificity retained after leucine zipper exchange between GCN4 and C/EBP. Science, 1989, 246(4932), 922-926.
66. Vinson, C.R.; Hai, T.; Boyd, S.M. Dimerization specificity of the leucine zipper-containing bZIP motif on DNA binding: Prediction and rational design. Genes Developm., 1993, 7(6), 1047-1058.
67. Newman, J.R.; Keating, A.E. Comprehensive identification of human bZIP interactions with coiled-coil arrays. Science, 2003, 300(5628), 2097-101.
68. Hendricks-Taylor, L.R.; Bachinski, L.L.; Siciliano, M.J.; Fertitta, A.; Trask, B.; de Jong, P.J.; Ledbetter, D.H.; Darlington, G.J., The CCAAT/enhancer binding protein (C/EBP alpha) gene (CEBPA) maps to human chromosome 19q13.1 and the related nuclear factor NF-IL6 (C/EBP beta) gene (CEBPB) maps to human chromosome 20q13.1. Genomics, 1992, 14(1), 12-17.
69. Ossipow, V.; Descombes, P.; Schibler, U., CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials. Proc. Natl. Acad. Sci. USA, 1993, 90(17), 8219-8223.
70. Lin, F.T.; MacDougald, O.A.; Diehl, A.M.; Lane, M.D. A 30-kDa alternative translation product of the CCAAT/enhancer binding protein alpha message: Transcriptional activator lacking antimitotic activity. Proc. Natl. Acad. Sci. USA, 1993, 90(20), 9606-9610.
71. Calkhoven, C.F.; Muller, C.; Leutz, A. Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Developm., 2000, 14(15), 1920-1932.
72. Chattopadhyay, S.; Gong, E.Y.; Hwang, M.; Park, E.; Lee, H.J.; Hong, C.Y.; Choi, H.S.; Cheong, J.H.; Kwon, H.B.; Lee, K. The CCAAT enhancer-binding protein-alpha negatively regulates the transactivation of androgen receptor in prostate cancer cells. Mol. Endocrinol., 2006, 20(5), 984-995.
73. Timchenko, N.A.; Wilde, M.; Darlington, G.J. C/EBPalpha regulates formation of S-phase-specific E2F-p107 complexes in livers of newborn mice. Mol. Cellul. Biol., 1999, 19(4), 2936-245.
74. Timchenko, N.A.; Wilde, M.; Nakanishi, M.; Smith, J.R.; Darlington, G.J. CCAAT/enhancer-binding protein alpha(C/EBP alpha) inhibits cell proliferation through the p21(WAF-1/CIP-1/SDI-1) protein. Genes Developm., 1996, 10(7), 804-815.
75. Timchenko, N Wilde, M.; Iakova, P.; Albrecht, J.H.; Darlington, GJ. E2F/p107 and E2F/p130 complexes are regulated by C/EBPalpha in 3T3-L1 adipocytes. Nucleic Acids Res., 1999, 27(17), 3621-3630.
76. Kovacs, K.A.; Steinmann, M.; Magistretti, P.J.; Halfon, O.; Cardinaux, J.R. CCAAT/enhancer-binding protein family members recruit the coactivator CREB-binding protein and trigger its phosphorylation. J. Biologic. Chem., 2003, 278(38), 36959-36965.
77. Cleaves, R.; Wang, Q.F.; Friedman, A.D. C/EBPalphap30, a myeloid leukemia oncoprotein, limits G-CSF receptor expression but not terminal granulopoiesis via site-selective inhibition of C/EBP DNA binding. Oncogene, 2004, 23(3), 716-725.
78. Wang, W.; Wang, X.; Ward, A.C.; Touw, I.P.; Friedman, A.D, C/EBPalpha and G-CSF receptor signals cooperate to induce the myeloperoxidase and neutrophil elastase genes. Leukemia, 2001, 15(5), 779-786.
79. Pabst, T.; Mueller, B.U.; Zhang, P.; Radomska, H.S.; Narravula, S.; Schnittger, S.; Behre, G.; Hiddemann, W.; Tenen, D.G., Dominant-negative mutations of CEBPA, encoding CCAAT/ enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat. Genet., 2001, 27(3), 263-270.
80. Gombart, A.F.; Hofmann, W.K.; Kawano, S.; Takeuchi, S.; Krug, U.; Kwok, S.H.; Larsen, R.J.; Asou, H.; Miller, C.W.; Hoelzer, D.; Koeffler, H.P. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood, 2002, 99(4), 1332-1340.
81. Lourenco, A.R.; Coffer, P.J. A tumor suppressor role for C/EBPalpha in solid tumors: More than fat and blood. Oncogene, 2017, 36(37), 5221-5230.
82. Tada, Y.; Brena, R.M.; Hackanson, B.; Morrison, C.; Otterson, G. A.; Plass, C. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J. Natl. Cancer Inst., 2006, 98(6), 396-406.
83. Lu, G.D.; Leung, C.H.; Yan, B.; Tan, C.M.; Low, S.Y.; Aung, M.O.; Salto-Tellez, M.; Lim, S.G.; Hooi, S.C. C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation. Gastroenterology, 2010, 139(2), 632-643, 643 e1-4.
84. Meissner, A.; Mikkelsen, T.S.; Gu, H.; Wernig, M.; Hanna, J.; Sivachenko, A.; Zhang, X.; Bernstein, B.E.; Nusbaum, C.; Jaffe, D.B.; Gnirke, A.; Jaenisch, R.; Lander, E.S. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature, 2008, 454(7205), 766-770.
85. Ong, C.T.; Corces, V.G. Enhancer function: New insights into the regulation of tissue-specific gene expression. Nat. Rev. Genet., 2011, 12(4), 283-293.
86. Avellino, R.; Havermans, M.; Erpelinck, C.; Sanders, M.A.; Hoogenboezem, R.; van de Werken, H.J.; Rombouts, E.; van Lom, K.; van Strien, P.M.; Gebhard, C.; Rehli, M.; Pimanda, J.; Beck, D.; Erkeland, S.; Kuiken, T.; de Looper, H.; Groschel, S.; Touw, I.; Bindels, E.; Delwel, R. An autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation. Blood, 2016, 127(24), 2991-3003.
87. Guo, H.; Ma, O.; Friedman, A.D. The Cebpa +37-kb enhancer directs transgene expression to myeloid progenitors and to long-term hematopoietic stem cells. J. Leukocyte Biol., 2014, 96(3), 419-426.
88. Kung, J.T.; Colognori, D.; Lee, J.T. Long noncoding RNAs: past, present, and future. Genetics, 2013, 193(3), 651-669.
89. Xiao, T.; Liu, L.; Li, H.; Sun, Y.; Luo, H.; Li, T.; Wang, S.; Dalton, S.; Zhao, R.C.; Chen, R. Long noncoding RNA ADINR regulates adipogenesis by transcriptionally activating C/EBPalpha. Stem Cell Reports, 2015, 5(5), 856-865.
90. Di Ruscio, A.; Ebralidze, A.K.; Benoukraf, T.; Amabile, G.; Goff, L.A.; Terragni, J.; Figueroa, M.E.; De Figueiredo Pontes, L.L.; Alberich-Jorda, M.; Zhang, P.; Wu, M.; D'Alo, F.; Melnick, A.; Leone, G.; Ebralidze, K.K.; Pradhan, S.; Rinn, J.L.; Tenen, D.G., DNMT1-interacting RNAs block gene-specific DNA methylation. Nature, 2013, 503(7476), 371-376.
91. Mischoulon, D.; Rana, B.; Bucher, N.L.; Farmer, S.R. Growth-dependent inhibition of CCAAT enhancer-binding protein (C/EBP alpha) gene expression during hepatocyte proliferation in the regenerating liver and in culture. Molecul. Cellul. Biol., 1992, 12(6), 2553-2560.
92. Trivedi, A.K.; Bararia, D.; Christopeit, M.; Peerzada, A.A.; Singh, S.M.; Kieser, A.; Hiddemann, W.; Behre, H.M.; Behre, G. Proteomic identification of C/EBP-DBD multiprotein complex: JNK1 activates stem cell regulator C/EBPalpha by inhibiting its ubiquitination. Oncogene, 2007, 26(12), 1789-1801.
93. Wang, C.; Ren, R.; Hu, H.; Tan, C.; Han, M.; Wang, X.; Zheng, Y. MiR-182 is up-regulated and targeting Cebpa in hepatocellular carcinoma. Chinese J. Cancer Res., 2014, 26(1), 17-29.
94. Timchenko, L.T.; Iakova, P.; Welm, A.L.; Cai, Z.J.; Timchenko, N. A. Calreticulin interacts with C/EBPalpha and C/EBPbeta mRNAs and represses translation of C/EBP proteins. Mol. Cellul. Biol., 2002, 22(20), 7242-7257.
95. Hattori, T.; Ohoka, N.; Inoue, Y.; Hayashi, H.; Onozaki, K., C/EBP family transcription factors are degraded by the proteasome but stabilized by forming dimer. Oncogene, 2003, 22(9), 1273-1280.
96. Subramanian, L.; Benson, M.D.; Iniguez-Lluhi, J.A. A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein alpha inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3. J. Biologic. Chem., 2003, 278(11), 9134-9141.
97. Miller, M.; Shuman, J.D.; Sebastian, T.; Dauter, Z.; Johnson, P.F. Structural basis for DNA recognition by the basic region leucine zipper transcription factor CCAAT/enhancer-binding protein alpha. J. Biologic. Chem., 2003, 278(17), 15178-15184.
98. Kato, N.; Kitaura, J.; Doki, N.; Komeno, Y.; Watanabe-Okochi, N.; Togami, K.; Nakahara, F.; Oki, T.; Enomoto, Y.; Fukuchi, Y.; Nakajima, H.; Harada, Y.; Harada, H.; Kitamura, T. Two types of C/EBPalpha mutations play distinct but collaborative roles in leukemogenesis: Lessons from clinical data and BMT models. Blood, 2011, 117(1), 221-233.
99. Leroy, H.; Roumier, C.; Huyghe, P.; Biggio, V.; Fenaux, P.; Preudhomme, C. CEBPA point mutations in hematological malignancies. Leukemia, 2005, 19(3), 329-334.
100. Wang, N.D.; Finegold, M.J.; Bradley, A.; Ou, C.N.; Abdelsayed, S. V.; Wilde, M.D.; Taylor, L.R.; Wilson, D.R.; Darlington, G.J. Impaired energy homeostasis in C/EBP alpha knockout mice. Science, 1995, 269(5227), 1108-1112.
101. Kimura, T.; Christoffels, V.M.; Chowdhury, S.; Iwase, K.; Matsuzaki, H.; Mori, M.; Lamers, W.H.; Darlington, G.J.; Takiguchi, M. Hypoglycemia-associated hyperammonemia caused by impaired expression of ornithine cycle enzyme genes in C/EBPalpha knockout mice. J. Biologic. Chem., 1998, 273(42), 27505-27510.
102. Benedict, M.; Zhang, X. Non-alcoholic fatty liver disease: An expanded review. World J. Hepatol., 2017, 9(16), 715-732.
103. Rajbhandari, R.; Chung, R.T. Treatment of hepatitis B: A concise review. Clin. Translat. Gastroenterol., 2016, 7(9), e190.
104. Manns, M.P.; Buti, M.; Gane, E.; Pawlotsky, J.M.; Razavi, H.; Terrault, N.; Younossi, Z. Hepatitis C virus infection. Nat. Rev.. Dis. Primers, 2017, 3, 17006.
105. Rasineni, K.; Casey, C.A. Molecular mechanism of alcoholic fatty liver. Ind. J. Pharmacol., 2012, 44(3), 299-303.
106. Tsochatzis, E.A.; Bosch, J.; Burroughs, A.K. Liver cirrhosis. Lancet, 2014, 383(9930), 1749-1761.
107. Llovet, J.M.; Zucman-Rossi, J.; Pikarsky, E.; Sangro, B.; Schwartz, M.; Sherman, M.; Gores, G., Hepatocellular carcinoma. Nat. Rev. Dis. Primers, 2016, 2, 16018.
108. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA, 2015, 65(2), 87-108.
109. London, W.T.M.K. Liver Cancer. In: Cancer Epidemiology and Prevention. 3rd ed.; Oxford University Press: New York: 2006; pp, 763-786.
110. El-Serag, H.B.; Marrero, J.A.; Rudolph, L.; Reddy, K.R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology, 2008, 134(6), 1752-1763.
111. Fan, S.T. Hepatocellular carcinoma--resection or transplant? Nat. Rev. Gastroenterol. Hepatol., 2012, 9(12), 732-737.
112. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2017. CA, 2017, 67(1), 7-30.
113. Adnane, L.; Trail, P.A.; Taylor, I.; Wilhelm, S.M., Sorafenib(BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol., 2006, 407, 597-612.
114. Sanoff, H.K.; Chang, Y.; Lund, J.L.; O'Neil, B.H.; Dusetzina, S.B. Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist, 2016, 21(9), 1113-1120.
115. Parikh, N.D.; Marshall, V.D.; Singal, A.G.; Nathan, H.; Lok, A.S.; Balkrishnan, R.; Shahinian, V. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. Hepatology, 2017, 65(1), 122-133.
116. Johansen, L.M.; Iwama, A.; Lodie, T.A.; Sasaki, K.; Felsher, D. W.; Golub, T.R.; Tenen, D.G. c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol. Cellul. Biol., 2001, 21(11), 3789-3806.
117. Timchenko, N.; Wilson, D.R.; Taylor, L.R.; Abdelsayed, S.; Wilde, M.; Sawadogo, M.; Darlington, G.J. Autoregulation of the human C/EBP alpha gene by stimulation of upstream stimulatory factor binding. Mol. Cellul. Biol., 1995, 15(3), 1192-1202.
118. Yogosawa, S.; Mizutani, S.; Ogawa, Y.; Izumi, T. Activin receptor-like kinase 7 suppresses lipolysis to accumulate fat in obesity through downregulation of peroxisome proliferator-activated receptor gamma and C/EBPalpha. Diabetes, 2013, 62(1), 115-123.
119. Smith, L.T.; Hohaus, S.; Gonzalez, D.A.; Dziennis, S.E.; Tenen, D. G. PU.1(Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood, 1996, 88(4), 1234-1247.
120. Tanaka, S.; Tanaka, K.; Magnusson, F.; Chung, Y.; Martinez, G. J.; Wang, Y.-H.; Nurieva, R.I.; Kurosaki, T.; Dong, C. CCAAT enhancer binding protein alpha (C/EBPα) negatively regulates IFN-γ Expression in T cells. J. Immunol., (Baltimore, Md.: 1950), 2014, 193(12), 6152-6160.
121. Soriano, H.E.; Kang, D.C.; Finegold, M.J.; Hicks, M.J.; Wang, N. D.; Harrison, W.; Darlington, G.J. Lack of C/EBP alpha gene expression results in increased DNA synthesis and an increased frequency of immortalization of freshly isolated mice [correction of rat] hepatocytes. Hepatology, 1998, 27(2), 392-401.
122. Lin, T.C.; Hou, H.A.; Chou, W.C.; Ou, D.L.; Yu, S.L.; Tien, H.F.; Lin, L.I. CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia. Leukemia, 2011, 25(1), 32-40.
123. Annamaneni, S.; Kagita, S.; Gorre, M.; Digumarti, R.R.; Satti, V.; Battini, M.R. Methylation status of CEBPA gene promoter in chronic myeloid leukemia. Hematology, 2014, 19(1), 42-44.
124. Kumagai, T.; Akagi, T.; Desmond, J.C.; Kawamata, N.; Gery, S.; Imai, Y.; Song, J.H.; Gui, D.; Said, J.; Koeffler, H.P. Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. Int. J. Cancer, 2009, 124(4), 827-833.
125. Lefterova, M.I.; Zhang, Y.; Steger, D.J.; Schupp, M.; Schug, J.; Cristancho, A.; Feng, D.; Zhuo, D.; Stoeckert, C.J., Jr.; Liu, X.S.; Lazar, M.A. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Developm., 2008, 22(21), 2941-2952.
126. Liu, X.; Liu, C.; Laurini, E.; Posocco, P.; Pricl, S.; Qu, F.; Rocchi, P.; Peng, L. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer. Mol. Pharm., 2012, 9(3), 470-481.
127. Lima, W.F.; Wu, H.; Nichols, J.G.; Sun, H.; Murray, H.M.; Crooke, S.T. Binding and cleavage specificities of human Argonaute2. J. Biologic. Chem., 2009, 284(38), 26017-26028.
128. Huan, H.; Wen, X.; Chen, X.; Wu, L.; Liu, W.; Habib, N.A.; Bie, P.; Xia, F. C/EBPalpha short-activating RNA suppresses metastasis of hepatocellular carcinoma through inhibiting EGFR/beta-catenin signaling mediated EMT. PLoS One, 2016, 11(4), e0153117.